Apr 02, 2024 8:00 am EDT Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission
Mar 21, 2024 11:04 am EDT MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor
Dec 04, 2023 8:00 am EST MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations
Nov 29, 2023 8:00 am EST MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%
Nov 21, 2023 10:42 am EST MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time
Nov 21, 2023 10:09 am EST MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a
Nov 20, 2023 8:00 am EST MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
Sep 18, 2023 8:30 am EDT MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot
Sep 05, 2023 8:31 am EDT MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts